Albumin News and Research

RSS

Standard TFI definition still applies for relapsed SCLC classification

Italian researchers have confirmed that using a treatment-free interval cut-off of 60 days to classify relapsed small-cell lung cancer as sensitive or resistant can be regarded as the standard definition.

23 Jul 2014

Standard risk factors stratify already high-risk diabetic patients

Cardiovascular disease risk factors are associated with mortality even among patients with Type 2 diabetes who are already at high risk due to having high coronary artery calcified plaque, say researchers.

4 Jul 2014

Five specific tests commonly performed in anesthesiology may not be necessary

Proving that less really is more, five specific tests or procedures commonly performed in anesthesiology that may not be necessary and, in some cases should be avoided, will be published online June 16 in JAMA Internal Medicine.

17 Jun 2014

Cardiac biomarkers aid microvascular risk prediction in diabetics

Assessing cardiac biomarkers results in a moderate improvement in the ability to predict microvascular complications in patients with Type 2 diabetes, say researchers.

6 Jun 2014

Improved glycemic control can slow progression of ESRD in type 1 diabetic people

People with type 1 diabetes who have developed kidney complications can slow the progression of their complications by improving control of their glycemic (blood glucose) levels over the long term.

6 Jun 2014

Compound in saliva may protect from toxins in tea, coffee and liquid smoke flavoring

A compound in saliva, along with common proteins in blood and muscle, may protect human cells from powerful toxins in tea, coffee and liquid smoke flavoring, according to results of a new study led by investigators at the Johns Hopkins Kimmel Cancer Center.

2 Jun 2014

Compound in saliva and proteins in blood may protect human cells from powerful toxins in tea, coffee

31 May 2014

Novozymes Biopharma to assess novel subunit vaccine candidate using Veltis technology

Novozymes Biopharma has entered a new collaborative research agreement with one of the world’s top vaccine companies. The partnership will enable the company to evaluate Novozymes Biopharma's modified recombinant human albumin (rAlbumin) Veltis technology, to assess the dosing and performance of a novel subunit antigen vaccine candidate.

30 May 2014

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

A drug's half-life indicates how long a substance will remain active in the body. It is essentially the period of time that it takes for the concentration of the amount of the drug to be reduced by half, and therefore, determines how frequently a drug needs to be administered to maintain its therapeutic effect.

27 May 2014

Novozymes Biopharma, ThioLogics to collaborate on drug-albumin conjugation platform

Novozymes Biopharma has entered a new collaboration with UK-based biotechnology company, ThioLogics. The collaboration brings together Novozymes' modified recombinant human albumin (rAlbumin) Veltis technology, with ThioLogics' site-specific next generation maleimide conjugation platform. This allows Novozymes to offer the pharma industry serum stable albumin drug conjugates with enhanced pharmacokinetic and/or targeting capabilities.

14 May 2014

5-year survival of diabetic kidney transplant patients now on par with nondiabetic recipients

Mayo Clinic researchers have discovered that the five-year survival of diabetic kidney transplant patients is now on par with the five-year survival of nondiabetic kidney recipients.

9 May 2014

Perfusion system at room temperature preserves and improves metabolic function of donor livers

A system developed by investigators at the Massachusetts General Hospital (MGH) Center for Engineering in Medicine (CEM) and the MGH Transplant Center has the potential to increase both the supply and the quality of donor organs for liver transplantation.

7 May 2014

Concert Pharmaceuticals reports results from CTP-499 Phase 2 trial in patients with diabetic kidney disease

Concert Pharmaceuticals, Inc. today announced 48-week results of its Phase 2 clinical trial of CTP-499 in patients with diabetic kidney disease. CTP-499, when used in addition to the standard of care, is being developed to delay the progression of these patients to end-stage renal failure, which requires dialysis or kidney transplantation.

26 Apr 2014

Drug used to treat hypertension prevents post-traumatic epilepsy in rodent model

Between 10 and 20 percent of all cases of epilepsy result from severe head injury, but a new drug promises to prevent post-traumatic seizures and may forestall further brain damage caused by seizures in those who already have epilepsy.

23 Apr 2014

Research by UCI, Salk Institute points to novel therapies for minimizing stroke-induced brain damage

By discovering a new mechanism that allows blood to enter the brain immediately after a stroke, researchers at UC Irvine and the Salk Institute have opened the door to new therapies that may limit or prevent stroke-induced brain damage.

18 Apr 2014

Baxter reports topline results from BAX 111 Phase 3 trial for treatment of von Willebrand disease

Baxter International Inc. today announced topline results from a Phase 3 clinical trial evaluating the safety, efficacy and pharmacokinetics (PK) of BAX 111. BAX 111 is a recombinant von Willebrand factor (rVWF) under investigation for the treatment of bleeding episodes in patients with von Willebrand disease, the most common type of inherited bleeding disorder.

From Baxter International Inc. 16 Apr 2014

Scientists uncover mechanism and possible treatment to reverse immune suppression in liver disease patients

The mechanism which underlies the susceptibility of liver disease patients to life-threatening infection has been uncovered by Wellcome Trust-funded medical scientists, who have also suggested a possible treatment to reverse immune suppression in these patients.

15 Apr 2014

Siemens, NKF form new alliance to improve screening for kidney disease in high-risk individuals

Siemens Healthcare and the National Kidney Foundation (NKF) announced today a new strategic alliance focusing on education, awareness and screening for kidney disease in high-risk individuals. This important collaboration will leverage the latest testing recommendations from the NKF to improve detection among the 73 million Americans at risk for kidney disease.

10 Apr 2014

Proprietary Novozymes technology used in GlaxoSmithKline’s new diabetes treatment

Novozymes Biopharma DK A/S, a subsidiary of Novozymes A/S, a world leader in bioinnovation, has announced that its albumin-based VELTIS half-life extension technology is being used by GlaxoSmithKline in the recently authorized Eperzan (albiglutide) for the treatment of type 2 diabetes in Europe.

1 Apr 2014

Bariatric surgery more effective than intensive medical therapy for managing type 2 diabetes

Gastric bypass and sleeve gastrectomy - two of the most commonly used bariatric surgeries - are more effective than intensive medical therapy alone when it comes to managing uncontrolled type 2 diabetes in overweight or obese patients after three years, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.